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Abstract 
Background: Chemotherapy-induced left ventricular dysfunction represents a major clinical problem, which is often 
only recognised at an advanced stage, when supportive therapy is ineffective. Although an early heart failure treat-
ment could positively influence the health status and clinical outcome, there is still no evidence of routine prophylac-
tic cardioprotection for the majority of patients without previous cardiovascular history awaiting potentially cardio-
toxic chemotherapy. In this study, we set out to investigate whether a prophylactic cardioprotective therapy relative 
to a conventionally scheduled heart failure treatment is more effective in preventing cardiotoxicity in a rodent model 
of doxorubicin (DOX)-induced cardiomyopathy.
Methods: Male Wistar rats (n = 7–11 per group) were divided into 4 subgroups, namely negative controls receiving 
intravenous saline (CON), positive controls receiving intravenous DOX (6 cycles; D-CON), and DOX-treated animals 
receiving either prophylactic (PRE, started 1 week before DOX) or conventionally applied (POST, started 1 month after 
DOX) combined heart failure therapy of oral bisoprolol, perindopril and eplerenone. Blood pressure, heart rate, body 
weight and echocardiographic parameters were monitored in vivo, whereas myocardial fibrosis, capillarisation, ultras-
tructure, myofilament function, apoptosis, oxidative stress and mitochondrial biogenesis were studied in vitro.
Results: The survival rate in the PRE group was significantly improved compared to D-CON (p = 0.0207). DOX 
increased the heart rate of the animals (p = 0.0193), while the blood pressure (p ≤ 0.0105) and heart rate (p = 0.0029) 
were significantly reduced in the PRE group compared to D-CON and POST. The ejection fraction remained pre-
served in the PRE group compared to D-CON or POST (p ≤ 0.0237), while none of the treatments could prevent the 
DOX-induced increase in the isovolumetric relaxation time. DOX decreased the rate of the actin-myosin cross-bridge 
cycle, irrespective of any treatment applied (p ≤ 0.0433). The myocardium of the D-CON and POST animals displayed 
pronounced ultrastructural damage, which was not apparent in the PRE group (p ≤ 0.033). While the DOX-induced 
apoptotic activity could be reduced in both the PRE and POST groups (p ≤ 0.0433), no treatment was able to prevent 
fibrotic remodelling or the disturbed mitochondrial biogenesis.
Conclusion: For attenuating DOX-induced adverse myocardial effects, prophylactic cardioprotection has many 
advantages compared to a late-applied treatment.
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Background
Worldwide, cancer is the second leading cause of death 
after cardiovascular diseases, but in 12 European Union 
countries it has recently taken the lead [1]. Although 
the survival rate of patients suffering from oncological 
diseases has significantly risen due to developments in 
modern oncotherapy, the cardiovascular side effects of 
chemotherapy and radiotherapy have placed limits on 
the success of oncotherapeutic strategies. Despite inten-
sive ongoing research efforts, chemotherapy-induced 
cardiotoxicity remains an unresolved clinical problem, 
which may lead to cardiomyopathy and consequently, 
heart failure, with an incidence varying over a wide range 
(0.2–48%) [2]. In recent years, the use of classic cytotoxic 
agents such as anthracyclines has been re-evaluated due 
to the evolving role of targeted and immuno-oncology 
therapies, however, they still have basic and important 
role in the treatment of many malignancies. Unsurpris-
ingly, most cardio-oncology related basic research has 
focused on doxorubicin (DOX), which belongs to the 
group of anthracyclines and is one of the most commonly 
applied chemotherapeutic agents with well-known car-
diotoxic side effects that calls for efficient therapeutic 
approaches to circumvent cardiotoxicity.
In tumour cells, the primary cytotoxic effect of DOX 
is executed through the inhibition of topoisomerase II 
and DNA intercalation leading to reactive oxygen spe-
cies production, DNA cross-linking and apoptosis [3]. 
The basic mechanism underlying DOX cardiotoxicity has 
not yet been completely elucidated, but one of the best 
accepted theories is that DOX interacts with iron metab-
olism and this leads to the formation of an anthracycline-
iron complex, which then induces lipid peroxidation, SH 
oxidation and DNA damage by reactive oxygen species 
production that in turn leads to contractile impairment, 
irreversible myocardial damage and fibrosis [4]. At the 
same time, other domains of DOX cardiotoxicity have 
also been proposed such as apoptosis, necrosis, inflam-
mation, mitochondrial damage, myofilament protein dys-
function, extracellular matrix remodelling, intracellular 
 Ca2+ dysregulation, etc. [5, 6].
Although many previous studies tested the hypotheti-
cal cardioprotective effects of various drug agents used in 
heart failure [7–16], as well as non-heart failure related 
substances in rodent models of DOX-induced cardio-
myopathy [17–32], no systematic investigation has been 
conducted to evaluate the effects of a clinically relevant 
combination therapy and no optimum timing of pre-
ventive measures has been established. Also, numerous 
previous studies disregarded many clinical aspects of 
human cancer management, hence they did not closely 
mimic the human pathology (e.g. a single high dose 
instead of consecutive cycles of DOX, intraperitoneal 
instead of intravenous DOX administration, cardiopro-
tective drug in the drinking water supply instead of oral 
gavage, etc.). Thus, a recent editorial stressed the need 
for horizontally integrating translational research for 
anthracycline cardiotoxicity and highlighted key criteria 
of experimental design, such as repetitive DOX cycles, 
intravenous administration, prophylactic cardioprotect-
ant regimen, etc. [33].
As for clinical prevention, the prophylactic applica-
tion of pharmacological agents with a mortality benefit 
in heart failure may in theory prevent or attenuate the 
degree of myocardial injury induced by DOX chemother-
apy. Secondary prevention of cardiotoxicity has already 
entered clinical practice when symptoms, increase in car-
diac biomarkers or overt heart failure develop, however, 
primary prevention is still in the research domain. One 
difficulty is the fact that a significant number of patients 
receiving chemotherapy are diagnosed with symptomatic 
heart failure already at an advanced stage, where the sec-
ondary preventive cardioprotective approach is incapable 
of reverting the adverse myocardial changes. Apparently, 
the prophylactic use of some studied substances (angio-
tensin converting enzyme inhibitors, angiotensin recep-
tor blockers, β-blockers) have been suggested in recent 
position statements, but exclusively for high risk patients 
with multiple risk factors for cardiotoxicity, who repre-
sent only a small fraction of the oncological population 
[2, 34, 35]. As a routine primary prophylaxis is not yet 
generally recommended in the larger population mainly 
due to the lack of sufficient randomised data from tri-
als with an appropriate sample size, further studies are 
essential to elucidate the cardioprotective effects of these 
drugs, their effective primary preventive dosage, the opti-
mum timing of therapy and possible unwelcome side 
effects as well [36]. Although smaller human trials on 
preventing cardiotoxicity mostly with single heart failure 
agents in patients undergoing chemotherapy are already 
available [37–46], the results are controversial and rou-
tine prophylactic cardioprotection has not yet entered 
clinical practice in case of the vast majority of onco-
logical patients without previous cardiovascular history. 
At present, only patients with symptoms or increased 
cardiac biomarker levels, or those at higher risk would 
qualify for treatment with heart failure medication, as 
recommended by current consensus guidelines in effect 
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[2, 34, 35]. With the current study, we challenge this 
practice and suggest that a prophylactic cardioprotective 
approach preceding the commencement of a potentially 
cardiotoxic chemotherapy may be beneficial in the unse-
lected larger population as well.
To mimic the human pathology and clinical manage-
ment we developed a rat model of DOX-induced car-
diomyopathy by applying a consecutive intravenous 
dosing protocol directly extrapolated from human chem-
otherapy. A set of in vivo and in vitro methodologies was 
employed to characterise myocardial changes of the ani-
mals, as well as to test the cardioprotective effects of a 
prophylactic heart failure treatment relative to a conven-
tionally scheduled one commenced only at a later stage. 
Our primary hypothesis was that the preventive applica-
tion of a combined supportive heart failure therapy pre-
ceding the cardiotoxic exposure may be more protective 
than that scheduled at a time when overt cardiac disease 
has already developed.
Methods
Animal experiments and study design
In our study, efforts were made to mimic the human 
pathology as close as possible. Our translational con-
cept and in vivo study protocol are presented on Fig. 1. 
Timing and dosing of intravenous DOX cycles were cal-
culated from existing human chemotherapy protocols 
and they were corrected to the lifespan, metabolism and 
body surface of rats [47]. Twelve-week-old Wistar rats 
(n = 7–11 per group) were used and divided into 4 sub-
groups. To avoid previously described effects of hormo-
nal differences in DOX cardiotoxicity [48], male rats were 
used exclusively in our study. The blood pressure (BP) 
and heart rate (HR) were monitored during the study by 
the tail-cuff method (CODA non-invasive blood pres-
sure monitoring system, Kent Scientific Corporation, 
Torrington, CT, USA). Following baseline BP, HR meas-
urements and echocardiography, animals in the prophy-
lactic group received a daily combination of gradually 
uptitrated oral bisoprolol (2.5 mg/kg), perindopril (2 mg/
kg) and eplerenone (6.25  mg/kg) started a week before 
DOX (PRE), while those in the post-exposure group had 
the same therapy started 1  month after the intravenous 
DOX treatment (POST). According to our concept, the 
PRE treatment represents a prophylactic cardioprotec-
tive approach for healthy subjects, which measure is 
currently missing from human practice, while the POST 
group represents subjects diagnosed with heart failure 
already at an advanced stage, where supportive therapy is 
often ineffective. The doses of the drugs applied were cal-
culated from existing recommendations for human heart 
failure and they were corrected to the metabolism and 
body surface of rats [49]. To ensure effective serum levels 
of the cardioprotective medications, drugs were applied 
in a mucous vehicle by oral gavage every day. Negative 
controls in the CON group and positive controls in the 
D-CON group received a drug-free vehicle (“placebo”; 
mucilago hydroxyethylcellulosi) orally throughout the 
study, while animals in the POST group had it until day 
51, then the drug-free vehicle was switched to an active 
heart failure therapy. The intravenous DOX exposure 
was carried out under light sedation (50  mg/kg keta-
mine, 5  mg/kg xylazine) by administering 1.5  mg/kg 
intravenous DOX into the tail veins of the animals in the 
D-CON, PRE and POST groups on 6 occasions (on the 
8th, 11th, 14th, 17th, 20th and 23rd days of the experi-
ment). Animals in the CON group received intravenous 
saline on the same days. Follow-up echocardiography was 
carried out under deep sedation (100  mg/kg ketamine, 
10 mg/kg xylazine) on days 51 and 80, while follow-up BP 
and HR measurements were performed on the 7th and 
39th days of the experiment. Following echocardiogra-
phy on day 80, animals were anaesthetised by intraperi-
toneal thiopental (100 mg/kg), their hearts were excised 
and frozen in liquid nitrogen and stored at − 70 °C. In the 
D-CON group, 4 out of 11 surviving animals were pre-
terminated on days 65–68 for clinical and ethical reasons 
to avoid imminent death and consequent loss of tissue 
material for the in  vitro measurements. These animals 
were not included in the survival plot.
Echocardiography
Echocardiography measurements were performed using 
a General Electric Vivid E9 ultrasound system equipped 
with a linear 14.1  MHz i13L probe (General Electric, 
Fairfield, CT, USA). For M mode based systolic param-
eters the parasternal long axis view was investigated. 
For diastolic and Doppler based systolic parameters, the 
4-chamber view was examined. To evaluate strain param-
eters, a short cine loop was recorded from the 4-chamber 
view. Due to technical reasons and strict criteria of image 
quality, we used only two segments of the septum (basal 
and mid) to assess the strain parameters. All echocardi-
ography images were obtained along with continuous 
electrocardiogram recording (limb leads).
Histology
A small piece of the left ventricular (LV) free wall was 
embedded into Shandon™ Cryomatrix (Thermo Fischer 
Scientific, Waltham, MA, USA). Fifteen µm thick sec-
tions were cut using Cryotome™ Cryostat (Thermo Fis-
cher Scientific, Waltham, MA, USA). After drying the 
sections, nuclei were stained with Mayer’s hemalum 
(VWR International, Radnor, PA, USA) for 10 min. Fol-
lowing 10 min of bluing, picrosirius red staining was per-
formed using a 0.1% solution. After rinsing in isopropyl 
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alcohol, sections were dehydrated and mounted using 
DPX (Sigma Aldrich, St. Louis, MO, USA). Slices were 
then investigated under an Olympus BX-50 microscope. 
Signs of fibrosis and capillary density were analysed 
from representative images using the ImageJ program 
(National Institutes of Health, Bethesda, Maryland, 
USA). Fibrosis was analysed on images at a magnifica-
tion of 40×. The fibrotic area was expressed relative to 
the overall myocardial area using the colour threshold 
function of the ImageJ program. Capillary density was 
analysed in a blinded fashion on images obtained with 
a 40× objective, which met the following criteria: they 
Fig. 1 Translational concept and in vivo study protocol. On the upper timeline, cardiac deterioration, symptom development and clinical 
management of a hypothetical oncological patient suffering from DOX-induced cardiotoxicity can be seen, who was diagnosed with heart 
failure at an advanced stage resulting in a poor prognosis. On the lower timeline, the in vivo study protocol of the animals can be seen based on 
a translational concept. Following baseline blood pressure, heart rate measurements and echocardiography, animals in the PRE group received a 
daily combination of gradually uptitrated oral bisoprolol, perindopril and eplerenone started a week before DOX, while those in the POST group 
had the same therapy started 1 month after the intravenous DOX treatment. According to our concept, the PRE treatment represents a prophylactic 
cardioprotective approach for healthy subjects, which measure is currently missing from human practice, while the POST group represents 
subjects diagnosed with heart failure already at an advanced stage, where supportive therapy is ineffective. Animals in the CON and D-CON groups 
received a drug-free vehicle (“placebo”) orally throughout the study, while those in the POST group had it until day 51, then the drug-free vehicle 
was switched to an active heart failure therapy. The intravenous DOX exposure was carried out on days 8, 11, 14, 17, 20 and 23 in the D-CON, 
PRE and POST groups, while animals in the CON group received intravenous saline on the same days. Follow-up blood pressure and heart rate 
measurements were performed on days 7 and 39, while follow-up echocardiography was carried out on days 51 and 80. AA aldosterone antagonist 
(eplerenone), ACEI angiotensin converting enzyme inhibitor (perindopril), BB β-blocker (bisoprolol), DOX doxorubicin, Echo echocardiography, HF 
heart failure, LV left ventricular
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represented cross-sectional cuts of myocardial sections, 
free of tissue wrinkles or staining artefacts. The relative 
number of capillaries and the relative capillary area were 
expressed by outlining all capillaries on the surface of the 
sections and also the overall myocardial area by freehand 
selections.
TUNEL assay
To detect apoptosis, we used the terminal deoxynucleoti-
dyl transferase (Tdt) nick end labelling test of the In Situ 
Cell Death Detection Kit, TMR (fluorescein-labelled cell 
markers) red (Roche, Mannheim, Germany). Apoptosis 
(DNA fragmentation) was detected by labelling the free 
3′-OH termini with modified nucleotides in an enzy-
matic reaction. The enzyme Tdt catalyses the template-
independent polymerisation of deoxyribonucleotides 
to the 3′-end of single- and double-stranded DNA. The 
steps of the sample preparation and imaging for TUNEL 
are described in Additional file 1. Apoptosis was quanti-
fied by the ratio of Tdt-positive nuclei/total nuclei in each 
section.
Electron microscopy
Tissue processing for electron microscopy was per-
formed using a modified version of Somogyi’s technique 
[50], which is described in Additional file 1. Representa-
tive pictures were taken using an Olympus Transmission 
Electron Microscope JEOL-1010 and iTEM software. The 
cardiomyocyte width was measured across the nucleus. 
To characterise DOX-induced ultrastructural changes, 
densitometry was employed on images displaying lon-
gitudinally sectioned myocardium acquired at a low 
magnification (3000×; 10–13 images/group) using the 
Image J program (National Institutes of Health, Bethesda, 
Maryland, USA) in a blinded fashion. Following a deter-
mination of the background density of an image (for 
white balance), cardiomyocytes were outlined by free-
hand selections, excluding all nuclei and any artefact. The 
area and mean density of each selection were then saved. 
The outlined DOX-induced ultrastructural myocardial 
changes (including myofibrillolysis, mitochondrial disin-
tegration and vacuolisation) all resulted in a lower overall 
density of the cardiomyocytes compared to an undam-
aged, healthy myocardium segment. The averaged mean 
densities of apparently intact sarcomeres served for 
exposition control. The final, background and exposition 
corrected mean densities of myocardium selections were 
weight-averaged for their respective area on the image.
Force measurements in isolated cardiomyocytes
The technique for force measurements in single, per-
meabilised cardiomyocyte preparations was described 
earlier [51–53]. Repeated activation–relaxation cycles 
were performed in single cardiomyocytes at 15  °C (to 
maintain the stability of the preparations), at a sar-
comere length of 2.2  μm. Isometric force values were 
normalised for the maximal  Ca2+-activated active force, 
and  Ca2+–force relations were fitted to a modified Hill 
equation to determine the  Ca2+-sensitivity of isometric-
force production, i.e.  pCa50. The active isometric force 
 (Fmax),  Ca2+-independent passive force  (Fpassive) and the 
rate constant of force redevelopment (ktr,max) were then 
assessed.  Fmax and  Fpassive were normalised for the car-
diomyocyte cross-sectional area, which was measured by 
using optically directed light.
Oxidative status of contractile proteins
Protein carbonyl group investigations were adapted from 
Balogh et  al. [53] using an Oxyblot Protein Oxydation 
Detection Kit (Merck Millipore, Burlington, MA, USA). 
The detailed steps of sample processing and signal detec-
tion are presented in Additional file 1.
Phosphorylation status of contractile proteins
To investigate protein phosphorylation, ProQ™ Diamond 
protein gel staining (Thermo Fisher Scientific, Waltham, 
MA, USA) was employed. The steps of tissue preparation 
and signal detection are described in Additional file 1.
Western immunoblot for mitochondrial proteins
Samples from the LV free wall were processed and 
labelled with the following antibodies being produced 
in a rabbit: anti-acetyl coenzyme A carboxylase (ACC), 
anti-phospho-ACC and anti-peroxisome proliferator-
activated receptor-gamma coactivator 1 alpha (PGC1α) 
(Cell Signaling Technology, Boston, MA, USA). The 
detailed steps of tissue processing and imaging are given 
in Additional file 1.
Western immunoblot for caspase‑3
Approximately 100  mg of heart tissue was used and 
labelled with an antibody against caspase-3. The steps 
of tissue preparation and visualisation are given in Addi-
tional file 1.
Data analysis and statistics
During the mechanical measurements,  Ca2+-induced 
contractions of the preparations were recorded with 
a custom-built LabVIEW Data Acquisition platform. 
The contractile parameters of the cardiomyocytes were 
analysed with the LabVIEW analysing software pack-
age (Myo; National Instruments, Austin, TX, USA) and 
Origin 6.0 (Originlab Corporation, Northampton, MA, 
USA). The signal intensities of protein bands were quan-
tified using the ImageJ (National Institutes of Health, 
Bethesda, Maryland, USA) and MagicPlot (MagicPlot 
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Systems, Saint Petersburg, Russia) software packages. 
Laboratory variables were measured multiple times, 
averaged within each animal and used in an analysis as 
a single value characteristic of that animal (“mean of the 
mean”; except for body weight, body mass index, strain 
imaging and biochemical measurements on Fig.  8). The 
sample size of the experimental groups is indicated on 
the figure panels, while the number of measurements is 
stated in the figure and table legends. Between-groups 
comparisons for the survival outcome were based on an 
overall log-rank test and all pairwise variants thereof. For 
all other outcomes, analysis of variance or the Kruskal–
Wallis test was applied for overall, and Student’s two-
sample t test or Wilcoxon’s rank-sum test for pairwise 
comparisons, as appropriate for distribution shapes. 
Values are given as mean ± standard error of the mean 
(SEM). The criterion for statistical significance was 
p ≤ 0.05. In the experiment, the statistical package uti-
lised was Stata (StataCorp LLC. 2017, Stata Statistical 
Software: Release 15. College Station, TX, USA).
Results
The clinical parameters of the animals are presented 
in detail in Table  1. The survival rate in the D-CON 
group was significantly worse compared to that in CON 
(p = 0.0247), but it remained preserved in the PRE group 
(p = 0.0207 vs. D-CON). Animals in the POST group 
were able to maintain their health status once combined 
heart failure therapy was commenced from the begin-
ning of day 52 (Fig. 2a). The thriving of animals (i.e. put-
ting on weight) exposed to DOX was significantly worse 
compared to that in CON, irrespective of any treatment 
applied (p ≤ 0.0018) (Fig.  2b). The heart rate and blood 
pressure were monitored until day 39. Afterwards the tail 
of the DOX-treated animals became stiff and sclerotic 
due to the direct effect of intravenous DOX, hindering 
reliable tail-cuff measurements. This is why the D-CON 
and POST animals were pooled during these examina-
tions, as up until then the treatment of the animals was 
identical (the POST treatment began only from day 52). 
DOX significantly increased the heart rate of the animals 
compared to that in CON [464 ± 19 vs. 406 ± 11 beats 
per minute (BPM), p = 0.0193], while the prophylac-
tic treatment of the PRE group significantly lowered the 
heart rate, the systolic and diastolic blood pressure com-
pared to CON and/or D-CON + POST (347 ± 7 BPM, 
p = 0.0074 vs. CON, p = 0.0029 vs. D-CON + POST; 
115 ± 5/85 ± 6 vs. 146 ± 6/110 ± 4  mmHg in PRE and 
D-CON + POST, respectively, p ≤ 0.0105) (Fig. 2c–e).
Echocardiographic data of the animals are presented in 
Table  2. At follow-up on day 80, a significantly reduced 
ejection fraction was seen in the D-CON group compared 
to that in CON (66.4 ± 3.6 vs. 84 ± 1.3%, p = 0.0043). This 
decrease was prevented by the prophylactic (81.3 ± 2%, 
p = 0.0046 vs. D-CON), but not by the conventionally 
scheduled treatment (72 ± 3.4%, p = 0.3886 vs. D-CON, 
p = 0.0237 vs. PRE) (Fig.  3a). A slight increase in the 
isovolumetric relaxation time (IVRT) was observed in 
the DOX-treated animals, which was statistically sig-
nificant in the POST animals compared to that in CON 
(34.1 ± 1.3 vs. 27.8 ± 1.4 ms, p = 0.006) (Fig. 3b). A slight 
decrease in the systolic longitudinal strain rate was 
observed in the DOX-treated groups, which was more 
apparent in the D-CON and POST groups than that in 
PRE [− 3.5 ± 0.4, − 4.1 ± 0.3, − 3.3 ± 0.8 vs. − 5 ± 0.9 
1/s in D-CON, PRE, POST and CON, respectively, 
p = 0.0321 (PRE vs. D-CON)] (Fig. 3c).
Picrosirius red staining revealed an increased fibrotic 
area (> 10%) in all DOX-exposed groups, irrespective of 
any treatment applied (p ≤ 0.0433) (Fig.  4a, b). A mild, 
statistically non-significant capillary rarefaction could be 
detected in the D-CON and POST groups compared to 
Table 1 Clinical parameters of the animals
BW body weight, DBP diastolic blood pressure, HR heart rate, SBP systolic blood pressure, tBMI body mass indexed for tibia length, n number of animals per group (5 
measurements per animal, except for single body weight and tBMI measurements)
* p ≤ 0.05 vs. CON; + p ≤ 0.05 vs. D-CON/D-CON + POST; § p ≤ 0.05 vs. PRE; ^ p ≤ 0.05 vs. POST; # p ≤ 0.05 vs. day 0
CON (n = 7) D‑CON (n = 7) PRE (n = 8) POST (n = 7)
Day 0 Day 74 Day 0 Day 74 Day 0 Day 74 Day 0 Day 74
BW (g) 309.29 ± 5.25^ 481.71 ± 14.37+§^# 333.43 ± 20.42 328.29 ± 10.91* 331.38 ± 10.86 342.25 ± 49.7* 339.71 ± 10.04* 311.71 ± 22.85*
tBMI (kg/m2) 157 ± 3.57+§^ 248.87 ± 8.74+§^# 194.78 ± 18.392* 189.9 ± 9.71* 187.91 ± 10.62* 189.72 ± 15.98* 206.45 ± 11.16* 190.52 ± 7.88*
CON (n = 7) D‑CON + POST (n = 16) PRE (n = 5–8)
Day 0 Day 7 Day 39 Day 0 Day 7 Day 39 Day 0 Day 7 Day 39
SBP (mmHg) 123.31 ± 3.05§ 134.51 ± 7.85§ 132.77 ± 8.11 132.61 ± 3.27§ 136.11 ± 2.47§ 145.91 ± 5.54§# 149.73 ± 4.98*+ 112.63 ± 4.3*+# 115.44 ± 5.19+#
DBP (mmHg) 92.23 ± 2.49§ 104.91 ± 7.35§# 103.34 ± 6.34 102.41 ± 3.23§ 103.64 ± 3.01§ 110.34 ± 4.39§ 116.75 ± 7.06*+ 83.3 ± 3.79*+# 85.24 ± 5.77+#
HR (1/min) 418.31 ± 7.27§ 419.2 ± 13.05§ 405.51 ± 11.18+§ 430.86 ± 11.73 435.75 ± 12.98§ 464.06 ± 19.36*§ 451.25 ± 11.81* 380.33 ± 10.41*+# 347.24 ± 6.59*+#
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CON or PRE, which was evident from the slight decrease 
in the relative number and relative area of capillaries 
(Fig. 4c, d). On electron microscopical examination, pro-
nounced ultrastructural changes were observed in the 
ultrathin myocardial sections obtained from the D-CON 
group, namely myofibrillolysis, vacuolisation, mitochon-
drial damage, Z-disc degradation and chromatin disin-
tegration in the nuclei. Samples from the POST animals 
displayed a visually similar ultrastructural pattern to 
those of the D-CON group, with less pronounced mito-
chondrial damage, while in the PRE group most of the 
above ultrastructural changes were not apparent—except 
for a mild degree of myofibrillolysis (Fig. 5A). Quantifica-
tion of the electron microscopic images by densitometry 
suggested a preserved myocardial ultrastructure in the 
PRE, but not in the POST group (p ≤ 0.0433) (Fig.  5B). 
On further analysis, a mild cardiomyocyte hypertrophy 
could be seen in the D-CON group (17 ± 0.9 µm), which 
was significant compared to that in PRE (14 ± 0.6  µm, 
p = 0.0301) (data not shown).
Mechanical measurements in single, permeabilised 
cardiomyocytes revealed no significant change in the 
 Ca2+-sensitivity  (pCa50), maximum  Ca2+-activated 
active or  Ca2+-independent passive force parameters of 
cellular preparations isolated from the groups (Fig. 6a, 
c, e–f; Table 3). However, a significant decrease in the 
ktr,max was observed in all DOX-exposed groups com-
pared to that in CON, which could not be prevented 
by any treatment applied (2.16 ± 0.20, 2.63 ± 0.42, 
2.04 ± 0.08 vs. 4.41 ± 0.26 in D-CON, PRE, POST and 
CON, respectively, p ≤ 0.0433) (Fig. 6b, d).
The TUNEL assay of the myocardial samples con-
firmed a significantly increased ratio of apoptotic 
nuclei in the D-CON group compared to that in CON 
(12.75 ± 2.35 vs. 4.85 ± 1.18%, p = 0.0209), which was 
not apparent in the PRE (1.79 ± 0.63%, p = 0.0209 vs. 
D-CON) or POST groups (3.62 ± 1.77%, p = 0.0433 
vs. D-CON) (Fig.  7a, b). A Western blot analysis 
revealed an increased level of caspase-3 in the myo-
cardial samples of the D-CON animals relative to that 
in CON [0.85 ± 0.12 vs. 0.58 ± 0.06 arbitrary units 
(AU), p = 0.05], which was markedly reduced by the 
prophylactic treatment in the PRE group (0.59 ± 0.05 
AU, p = 0.089 vs. D-CON), but not by the conven-
tionally scheduled therapy applied in the POST group 
Fig. 2 Survival and clinical parameters of the animals. The survival rate in the D-CON group was significantly worse compared to that in CON, but it 
remained preserved in the PRE group (a). The body weight was significantly lower in groups exposed to DOX compared to that in CON, irrespective 
of any treatment applied (b). DOX significantly increased the heart rate of animals, while the prophylactic treatment in the PRE group significantly 
decreased the blood pressure and heart rate (c–e). DBP diastolic blood pressure, HR heart rate, SBP systolic blood pressure. Lines at top represent 
doxorubicin exposure (DOX), prophylactic (PRE) or conventionally scheduled heart failure treatment (POST), respectively. n number of animals per 
group (5 measurements per animal, except for single body weight measurements); Statistics: Wilcoxon’s rank-sum test except for survival (log-rank 
test); *p ≤ 0.05 vs. CON; +p ≤ 0.05 vs. D-CON/D-CON + POST; §p ≤ 0.05 vs. PRE; ^p ≤ 0.05 vs. POST; #p ≤ 0.05 vs. day 0
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(0.72 ± 0.01 AU, p > 0.9999 vs. D-CON, p = 0.0321 vs. 
PRE) (Fig. 7c).
To explore underlying molecular events behind the 
changes in the mitochondrial system of cardiomyo-
cytes—which seem to be in the centre of DOX-induced 
cardiotoxicity—we characterised members of the cellular 
energy sensor web, PGC1α and adenosine monophos-
phate-activated protein kinase activity (by assessing the 
phosphorylation of ACC, its substrate). A Western blot 
analysis of PGC1α revealed significantly decreased levels 
in the DOX-treated animals, irrespective of any treatment 
applied (0.41 ± 0.1, 0.36 ± 0.11, 0.28 ± 0.07 vs. 0.96 ± 0.17 
AU in D-CON, PRE, POST and CON, respectively, 
p ≤ 0.009) (Fig. 8a). Moreover, a non-significant increase 
of P-ACC/ACC ratios was observed in the D-CON group 
compared to that in CON (1.36 ± 0.18 vs. 0.89 ± 0.24 AU, 
p = 0.0881) (Fig.  8b). The ProQ™ Diamond gel staining 
revealed a non-significant increase in the phosphoryla-
tion level of a ~ 31  kDa protein co-migrating with car-
diac troponin I in the D-CON group compared to that in 
PRE (1.56 ± 0.3 vs. 0.76 ± 0.11, p = 0.0782) (Fig.  8c). No 
changes were observed in the total phosphorylation of 
other contractile proteins. A gross analysis of the bands 
on the Oxyblot did not reveal any significant differences 
between the groups (data not shown).
Discussion
The cardiotoxicity of modern oncotherapy represents 
not only a great clinical challenge, but also a heavy bur-
den on cancer patients, their treating physicians and on 
society as well. Myocardial dysfunction and heart fail-
ure may be serious complications of chemotherapy with 
varying incidence [2]. Cardio-oncology is a relatively new 
and emerging discipline for the cardiovascular surveil-
lance of oncological patients, in order to achieve success-
ful oncotherapy with reduced myocardial harm, thereby 
improving the long-term survival rate and quality of life 
of patients. The present translational study sheds light 
on the importance of primarily applied prophylactic car-
dioprotection, which resulted in (1) an improved survival 
rate, (2) preserved systolic LV function and (3) conserva-
tion of the myocardial ultrastructure in our model. None 
of these beneficial effects were observed when the car-
dioprotective therapy was applied at a later stage. In the 
Fig. 3 Echocardiographic parameters of the animals. At follow-up, a significantly reduced ejection fraction was seen in the D-CON and POST 
groups compared to CON, while the ejection fraction in the PRE group remained preserved (a). A slight increase in the IVRT was observed in the 
DOX-treated animals, which was statistically significant in the POST animals compared to that in CON (b). A slight decrease in the longitudinal strain 
rate was observed in the DOX-treated animals, which was more apparent in the D-CON and POST groups (c). Representative recordings of M-mode 
and Doppler mode echocardiography (d). Illustration of strain imaging in the rat heart (e). IVRT = isovolumetric relaxation time. n number of animals 
per group (3 measurements per animal, except for single strain measurements); Statistics: Wilcoxon’s rank-sum test; *p ≤ 0.05 vs. CON; +p ≤ 0.05 vs. 
D-CON; §p ≤ 0.05 vs. PRE; ^p ≤ 0.05 vs. POST; #p ≤ 0.05 vs. day 0; †p ≤ 0.05 vs. day 51
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current work, efforts were made to design a clinically rel-
evant study concept by closely mimicking a current onco-
therapeutic approach of patients. An array of in vivo and 
in vitro methods were employed, including the relatively 
novel strain imaging, which is rarely applied in small ani-
mals mainly due to technical difficulties. We investigated 
several domains of DOX cardiotoxicity in vitro that may 
be interfered with the cardioprotective therapy applied 
(fibrosis, apoptosis, myofilament structure and function, 
oxidative stress, mitochondrial biogenesis).
Previously, Santos et al. investigated the structural and 
functional characteristics of mitochondria isolated from 
the hearts of DOX-receiving rats treated with carve-
dilol. According to their results, carvedilol was capable 
of preserving mitochondrial respiratory parameters and 
prevented mitochondrial damage. They also showed via 
electron microscopic imaging that the DOX-exposed 
myocardium displayed pronounced vacuolisation, which 
could not be seen in samples taken from the carvedilol 
group [54]. Similar beneficial effects on mitochondrial 
function and adenosine triphosphate production were 
shown by Hiona et  al. when they tested the effects of 
enalapril in a rat model of DOX-induced cardiomyopa-
thy [10]. In our model, we captured the above described 
electron microscopic pattern of vacuolisation in the 
D-CON group, but not in the PRE group. We also dem-
onstrated a disturbed mitochondrial morphology in the 
D-CON group coinciding with reduced expression of a 
key nuclear orchestrator of mitochondrial biogenesis, 
PGC1α. These findings are consistent with previous 
data, where reduced expression of PGC1α accompa-
nied cardiovascular lesions [55–57] and the induction of 
Fig. 4 Myocardial fibrosis and capillary density. a Representative images of myocardial sections stained with picrosirius red and Mayer’s hemalum in 
all groups. The red colour identifies fibrosis. b Increased fibrotic area was detected in all DOX-exposed groups, irrespective of any treatment applied. 
c, d A mild, statistically non-significant capillary rarefaction could be detected in the D-CON and POST groups compared to CON or PRE, which was 
evident from the slight decrease in the relative number and relative area of capillaries. n number of animals per group (9 images per animal for 
fibrosis, 1–4 images per animal for capillary density); Statistics: Wilcoxon’s rank-sum test; numbers are p values; NS: non-significant
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mitochondrial biogenesis was protective against DOX-
cardiotoxicity [58]. Although the prophylactic treat-
ment in our PRE group led to a preserved mitochondrial 
ultrastructure, it was not able to prevent the decrease in 
PGC1α.
Doxorubicin is thought to increase the production 
of reactive oxygen species [5]. These introduce oxi-
dative stress and may damage various cellular struc-
tures, including the mitochondria. As mitochondria 
are essential in cellular energetics, their dysfunction 
also leads to free radical production and this further 
increases the level of oxidative stress. In a prior study 
the free radical production of DOX-exposed cultured 
rat cardiomyocytes could be alleviated by carvedilol but 
not by atenolol [59]. Similar beneficial effects of enal-
april were described in  vivo in rats [10], while capto-
pril and telmisartan were found to be equally effective 
in reducing the level of oxidative stress markers [16]. In 
our study, we observed a slight increase in ACC phos-
phorylation in the D-CON group, which was normal-
ised to some extent in the PRE and POST groups. This 
suggests that the pharmacological treatment applied 
may alleviate energetic stress presented to the car-
diomyocytes. However, this effect was statistically not 
significant and a gross analysis of oxidative stress by 
protein carbonylation did not reveal any differences 
between the groups. When comparing our results with 
previous literature findings, the divergence in certain 
parameters may be accounted for by the differences in 
the models and protocols used, and also by possible 
unique features of the previously studied drugs, which 
may not always be apparent with other agents used in 
our study.
Myofibrillar degeneration and myofilament protein 
dysfunction are both representants of DOX-induced car-
diotoxicity. A number of studies demonstrated detailed 
histological and electron microscopic data of DOX-
induced myocardial changes, such as myofibrillar disar-
ray [60], myofibrillolysis, sarcomeric disintegration [9, 
61], contraction band formation [10], and cardiomyocyte 
hypertrophy [61, 62]. Some of these abnormalities were 
successfully attenuated by inhibiting the renin–angio-
tensin–aldosterone system [10, 15, 16]. In contrast with 
a conventionally scheduled therapy, we demonstrated a 
well-preserved ultrastructure of the myofilaments when 
applying a prophylactic treatment, which highlights the 
importance of the temporal aspects of cardioprotection 
in preserving myocardial ultrastructure.
Fig. 5 Electron microscopic imaging. A Pronounced ultrastructural changes were seen in the ultrathin myocardial sections obtained from the 
D-CON group: myofibrillolysis (d), vacuolisation (c, arrow), mitochondrial damage (c, arrowhead), Z-disc degradation (b, d, arrow) and chromatin 
disintegration in the nuclei (a, arrow). Samples from the POST animals displayed a visually similar ultrastructural pattern to those from the D-CON 
group, with less pronounced mitochondrial damage, while in the PRE group, most of the above ultrastructural changes were not apparent—except 
for a mild degree of myofibrillolysis. B Densitometry suggested a preserved myocardial ultrastructure in the PRE, but not in the POST group. AU 
optical density in arbitrary units. n number of animals per group (1-6 images per animal); Statistics: Wilcoxon’s rank-sum test; numbers are p values; 
NS non-significant
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In our study, we employed a unique mechanical meas-
uring system to characterise contractile properties of 
isolated cardiomyocytes. Although we did not find any 
significant differences in most contractile parameters of 
the cardiomyocytes from the different groups, the sig-
nificantly decreased ktr,max value measured in the DOX-
exposed cardiomyocytes suggests that the actin-myosin 
cross-bridge cycle of these myofilaments might be dis-
rupted by DOX. Although a slight increase in the phos-
phorylation level of troponin I could be observed in the 
D-CON group, it did not reach statistical significance 
and was not accompanied with any robust change in the 
 Ca2+-sensitivity of the cardiomyocytes isolated from this 
group.
Fibrosis represents another domain of DOX cardiomy-
opathy, which is also the subject of intensive preclinical 
research. Carvedilol [7], captopril [16], telmisartan [16] 
and spironolactone [63] have all been found to decrease 
DOX-induced myocardial fibrosis in small animals. 
Despite this, studies examining eplerenone gave either 
negative [12] or inconclusive results [13] when tested 
for the reversibility of DOX-induced interstitial fibrosis 
in mice. Interestingly, the combined application of our 
study drugs did not result in any significant improvement 
in the DOX-induced overall increase in fibrosis, regard-
less of the time span of the treatment. However, based 
on the mild differences seen in capillary density among 
the groups, we assume that the increase in the amount 
of myocardial collagen in the D-CON and POST animals 
might be the result of a more pronounced replacement 
fibrosis in response to cardiomyocyte cell death. In con-
trast, the relatively preserved capillarisation along with 
the increased collagen amount in the PRE group implies 
that the myocardial remodelling process in these animals 
could involve interstitial/perivascular fibrosis that might 
spare the cardiomyocytes. This hypothesis could also 
explain the preserved ejection fraction of these animals 
despite their increased fibrotic levels. However, the dif-
ferences in capillary density among the groups were sta-
tistically non-significant, hence further investigations 
are necessary to draw firm conclusions from it. Overall, 
fibrosis in the present study is likely to play only a mar-
ginal role in the systolic LV dysfunction of the animals 
in the D-CON group, while other mechanisms, such as 
apoptosis could be more important here.
Apoptosis is often referenced as a main contribu-
tor to DOX-induced myocardial damage. Apoptotic 
cardiomyocytes can be identified by various assays 
(e.g. TUNEL) detecting DNA damage and fragmenta-
tion. Previously, many research groups examined the 
preventability of DNA damage in experimental DOX 
cardiomyopathy [7, 59, 63]. In accordance with their 
results, we successfully demonstrated that both the 
prophylactic and the conventionally scheduled therapy 
significantly reduce the degree of DNA fragmentation 
captured by TUNEL. At the same time, the caspase-3 
activity, which is a biomarker of apoptosis, could only 
be substantially reduced by the prophylactic treat-
ment, and not by the conventional therapy. Previously, 
Hiona et al. failed to demonstrate attenuating effects of 
enalapril on increased caspase-3 and caspase-9 activi-
ties in a rat model of DOX cardiomyopathy [10], while 
Fig. 6 Force measurements in isolated cardiomyocytes. No 
significant change in the  Ca2+-sensitivity  (pCa50, a, c), active (e) or 
passive force values (f) could be detected, but a significant decrease 
in the ktr,max was observed in all DOX-exposed groups, which could 
not be prevented by any treatment applied (b, d). Illustration of an 
isolated cardiomyocyte.  pCa50 = Ca2+-sensitivity of isometric force 
production, ktr,max = rate constant of force redevelopment. n number 
of animals per group (2–4 cardiomyocytes per animal); Statistics: 
Wilcoxon’s rank-sum test; numbers are p values; NS: non-significant
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Spallarossa et  al. found alleviating effects of carvedilol 
but not atenolol on caspase-3 activity in rat cardiomyo-
cyte cultures exposed to DOX [59]. We think that in our 
model the previously described anti-apoptotic effect of 
perindopril [64] might play a key role in the attenuation 
of apoptosis of these cardiomyocytes, which could be 
attributed to the preservation of LV systolic function, 
especially in the PRE group, where animals received 
perindopril for an extended period of time.
Conclusions
Overall, we demonstrated that a prophylactic, combined 
cardioprotective approach has many advantages com-
pared to a conventionally scheduled heart failure therapy 
in attenuating DOX-induced cardiotoxicity. The signifi-
cantly improved survival rate of the animals receiving 
prophylactic cardioprotection was not only accompanied 
by a preserved systolic LV function, but also by a con-
servation of the myocardial ultrastructure. We suggest 
that the marked reduction in cardiomyocyte apoptosis 
may be responsible for the observed beneficial effects of 
prophylactic cardioprotection. Our findings may indi-
cate that a wider range of oncological patients awaiting 
anthracycline chemotherapy could benefit from prophy-
lactic cardioprotection after an appropriate risk–benefit 
evaluation. Within the controversy of already available 
human data, our animal model might facilitate scientific 
progress in this field and it could be an important early 
step in the process of laying down the fundaments of new 
clinical practice. Still, no matter the intention for an ade-
quate translational setting, preclinical testing in rodent 
models inevitably presents limitations to the extrapola-
tion of data to the human condition. Thus, in the future, 
further validation by human clinical studies assessing 
Table 3 Contractile parameters of isolated cardiomyocytes
Fmax maximum  Ca
2+-activated active force, Fpassive  Ca
2+-independent passive 
force, pCa50  Ca
2+-sensitivity of isometric-force production, ktr,max rate constant of 
force redevelopment, nHill steepness of the force-pCa curve characterising the 
cooperativity between myofilament units, n number of animals per group (2–4 
cardiomyocytes per animal)
* p ≤ 0.05 vs. CON; + p ≤ 0.05 vs. D-CON; § p ≤ 0.05 vs. PRE; ^ p ≤ 0.05 vs. POST
CON (n = 4) D‑CON 
(n = 4)
PRE (n = 4) POST (n = 4)
Fmax (kN/m
2) 16.1 ± 1.98 14 ± 3.47 14.49 ± 2.28 12.92 ± 0.98
Fpassive (kN/m
2) 1.08 ± 0.19 0.76 ± 0.14 1.26 ± 0.33 0.97 ± 0.14
pCa50 5.81 ± 0.02 5.77 ± 0.03 5.83 ± 0.02 5.78 ± 0.04
ktr,max (1/s) 4.41 ± 0.26+§^ 2.16 ± 0.2* 2.63 ± 0.42* 2.04 ± 0.08*
nHill 2.63 ± 0.21 2.56 ± 0.09 2.44 ± 0.14 2.47 ± 0.13
Fig. 7 TUNEL assay and caspase-3 levels detecting apoptotic activity. a Representative images of cardiomyocyte apoptosis detected by TUNEL. The 
blue colour denotes all nuclei, the red colour denotes DNA damage, while the purple colour on the merged images denotes nuclei of apoptotic 
cardiomyocytes. b A significantly increased ratio of apoptotic nuclei in the D-CON group was detected, which was not apparent in the PRE or POST 
group. c The increased caspase-3 levels observed in the D-CON animals were markedly reduced in the PRE group, but not in the POST group. AU 
optical density in arbitrary units, RI relative intensity. n number of animals per group (8 images per animal for TUNEL, 3-5 measurements per animal 
for caspase-3); Statistics: Wilcoxon’s rank-sum test; numbers are p values
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prophylactic, low dose, combination heart failure therapy 
is necessary in oncological patients awaiting anthracy-
cline chemotherapy.
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